Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03142724 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
A Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03142724: Completed Phase 1 study, sponsored by Molecular NeuroImaging.
NCT03142724 is a Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03142724, a Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.
Primary Outcome
Volumes of interest (VOI) will be placed on the visually identified source organs, and subsequently used for all the study PET frames. Activity within these volumes of interest is expressed in units of total radioactivity (kBq). Radioactivity will be corrected for body attenuation, but not for decay, and time activity data (TAC) generated for each source organ.
Interventions
- DRUG [18F]MNI-968
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 1 |
What the finished NCT03142724 record still lists
NCT03142724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-968 is the first listed.
NCT03142724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03142724 about?
NCT03142724 is a clinical study titled "Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects". The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.
What is the current status of trial NCT03142724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-05-01. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT03142724?
The interventions under investigation include: [18F]MNI-968 (DRUG).
Who is sponsoring clinical trial NCT03142724?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03142724's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI